A Phase 3 interventional study of Subcutaneous (SC) Abatacept and Intravenous (IV) Abatacept in Rheumatoid Arthritis (RA), sponsored by Bristol-Myers Squibb. Completed at 204 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-09.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one has the largest enrollment, is one of 3 that started in 2008, is one of 26 in phase 3, and was the 19th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,492 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one has the largest enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2008, is one of 22 in phase 3, and was the 21st registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
An Anti-TNF Failure Sub-study was initiated (recruited separately from Main study) using the same treatment as the Main study in order to assess the immunogenicity and safety in the Anti-TNF Failure population. The Sub-study terminated due to low recruitment and participants were permitted to roll into the LT Open Label Period.
Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
Drug: Subcutaneous (SC) Abatacept
Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
Drug: Intravenous (IV) Abatacept
Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
Also known as: Orencia, BMS-188667
Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo). 500mg (for body weight up to 60 kg) 750 mg (body weight between 61 and 100 kg) 1g (body weight above 100 kg)infusions
Also known as: Orencia, BMS-188667
Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169
The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).
Time frame: Day 169
Anti-TNF Failure Sub-Study Double Blind Period : Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Response in Anti-TNF Failure Population
Serum samples from all treated adult participants with active rheumatoid arthritis who were from the Anti-TNF failure population were screened for the presence of drug-specific antibodies using Enzyme Linked Immunoabsorbant Assay (ELISA). The number of participants who had the presence of anti-abatacept antibodies or anti-CTLA-4 antibodies present in their serum are summarized.
Time frame: Days 85, and 169 and postvisits on Days 28, 56, and 85
Double-blind Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Day 169
The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.
Time frame: Day 169
Double-blind Period: Mean Baseline Health Assessment Questionnaire Disability Index (HAQ-DI) for Participants With Assessments at Day 169
The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered.
Time frame: Day 169
Double-blind Period: Adjusted Mean Change From Baseline to Day 169 in HAQ-DI
The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0.
Time frame: Baseline to Day 169
Double-blind Period: Number of Participants Achieving Clinically Meaningful HAQ-DI Response at Day 169
The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ-DI response=an improvement of at least 0.3 units from baseline in HAQ-DI.
Time frame: Day 169
Double-blind Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation
AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug
Time frame: Day 1 to 56 days after last dose in short-term or first dose in the long-term, whichever occurs first.
Anti-TNF Failure Sub-study Double-blind Period: Number of Participants With SAEs, AEs Leading to Discontinuation or Who Died
AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Time frame: Day 1 to 56 days after last dose in short-term or first dose in the long-term, whichever occurs first.
Double-blind Period: Number of Participants With AEs of Special Interest
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections,serious infections,and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (prespecified AEs occurring within 1 hr of start of infusion), peri-infusional AEs (prespecified AEs occurring within 24 hrs of the start of infusion), system injection reactions, and local injection site reactions
Time frame: Day 1 up to 56 days post last dose in short- term period or first dose in the long -term period, whichever occurs first.
Double-blind Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements
Vital sign measurements were performed for participants before and after infusion/subcutaneous injection of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.
Time frame: Day 1 through end of short-term period (Day 169)
Double-blind Period: Number of Participants With Hematology Laboratory Test Results Meeting the Criteria for Marked Abnormality
ULN=upper limit of normal; LLN=lower limit of normal; BL= baseline. Marked abnormality criteria: Hemoglobin: \>3 g/dL decrease from BL; hematocrit: \<0.75\*BL; erythrocytes: \<0.75\*BL; platelets: \<0.67\*LLN/\>1.5\*ULN, or if BL\<LLN, use \<0.5\*BL and \<100,000 mm\^3; leukocytes: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN use \<0.8\*BL or \>ULN, or if BL\>ULN, use \>1.2\*BL or \<LLN; neutrophils+bands: \<1.0\*10\^3 c/uL; eosinophils: \>0.750\*10\^3 c/uL; basophils: \>400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750\*10\^3 c/uL/\>7.50\*10\^3 c/uL.
Time frame: Day 1 through end of short-term period (Day 169)
Double-blind Period: Number of Participants With Liver Function Laboratory Test Results Meeting the Criteria for Marked Abnormality
Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\*ULN, or if BL\>ULN, use \>3\*BL; aspartate aminotransferase (AST): \>3\*ULN, or if BL\>ULN, use \>4\*BL; alanine aminotransferase (ALT): \>3\*ULN, or if BL\>ULN, use \>4\*BL; G-glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN, use \>3\*BL; bilirubin: \>2\* ULN, or if BL\>ULN, use \>4\*BL; blood urea nitrogen: \>2\* BL; creatinine: \>1.5\*BL
Time frame: Day 1 through end of short-term period (Day 169)
Double-blind Period: Number of Participants With Electrolyte Laboratory Test Results Meeting the Criteria for Marked Abnormality
Marked abnormality criteria: Sodium: \<0.95\*LLN/\>1.05\*ULN, or if BL\<LLN, use \<0.95\* BL or \>ULN, or if BL\>ULN, use\>1.05\* BL or \<LLN; potassium: \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN, use\>1.1\* BL or \<LLN; chlorine: \<0.9\*LLN/\>1.1\* ULN, or if BL\<LLN, use \<0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN; calcium: \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN, use \<0.75\*BL or \>ULN, or if BL\>ULN, use\>1.25\* BL or \<LLN; phosphorous: \<0.75\* LLN/\>1.25\*ULN, or if BL\<LLN, use 0.67\*BL or \>ULN, or if BL\>ULN, use\>1.33\* BL or \<LLN
Time frame: Day 1 through end of short-term period (Day 169)
Double-blind Period: Minimum Observed Serum Concentration of Abatacept
Time frame: Days 57, 85, 113, 120, 127, 134, 141, and 169
Anti-TNF Failure Sub-study Double-blind Period: Minimum Observed Serum Concentration (Cmin) of Abatacept
Serum concentrations of abatacept were analyzed using a validated ELISA. Steady-state trough observed concentration in serum (Cminss) was measured in μg/mL. Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169.
Time frame: Days 57, 85, 113, 120, 127, 134, 141, and 169 (ST Period)
Double-blind Period: Maximum Observed Serum Concentration of Abatacept
Time frame: End of infusion on Days 1 and 113 for IV infusion and in the dosing interval of Days 113 to 120 for subcutaneous
Anti-TNF Failure Substudy Double Blind Period: Geometric Mean Maximum Observed Serum Concentration of Abatacept
Serum concentrations of abatacept were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169. Cmax was measured in micrograms per milliliter (μg/mL).
Time frame: End of infusion on Days 1 and 113 for IV infusion and in the dosing interval of Days 113 to 120 for subcutaneous
Double-blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept
Time frame: Dosing interval between Days 113 and 141 (TAU=28 days)
Anti-TNF Failure Sub-study Double Blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept
Serum concentrations of abatacept were analyzed using a validated ELISA. AUC(TAU) was measured as μg\*h/mL. Samples for AUC (TAU) were obtained on Days 113, 120, 127, 134, and 141.
Time frame: Dosing Interval between Days 113 and 141 (TAU=28 days)
Double-blind Period: Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Responses Over Time by Enzyme Linked Immunoabsorbant Assay (ELISA)
Serum samples from all treated adult participants with active rheumatoid arthritis were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept (anti-ABA) or anti-CTLA4 antibody (anti-CTLA4).
Time frame: Days 85, and 169 and postvisits on Days 28, 56, and 85
Double-blind Period: Time-matched Median Percent Change From Baseline in Levels of Serum C-reactive Protein Over the Short-term Period
C-reactive protein is an acute phase reactant protein that is a clinical marker for rheumatoid arthritis. Time-matched median percent change from baseline= (time-matched baseline value - Post-baseline value)/time-matched baseline value\*100, where the time-matched baseline value represents the median baseline value for only that cohort of participants with measurements available at that visit.
Time frame: Baseline to Days 15, 29, 57, 85, 113, 141, and 169
Double-blind Period: Number of Participants With Positive Anti-abatacept Responses Over Time by Electrochemiluminescence Immunoassay Among the First 10% of Participants Randomized
An electrochemiluminescence immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; abatacept molecule). Ig and/or Junction (JNCT) category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a postbaseline titer higher than Baseline, or any postbaseline positivity if Baseline value was missing. Trt=treatment.
Time frame: Days 85, and 169 and postvisits on Days 28, 56, and 85
Double-blind Period: Number of Participants Seroconverting by Day 169 According to Status (Negative or Positive) at Baseline
Rheumatoid factor (RF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.
Time frame: Baseline to Day 169
Open-Label LT Period: Number of Participants Achieving ACR 20 Response at Days 169, 729, 1261, and 1821
The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).
Time frame: Days 169, 729, 1261, 1821
Open-Label LT Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Days 169, 729, 1261, 1821
The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.
Time frame: Days 169, 729, 1261, 1821
Open-Label LT Period: Mean Change From Baseline in Disease Activity Score in 28 Joints (DAS28) Using C-reactive Protein (CRP) at Days 169, 729, 1261, 1821
The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6. A clinically significant response= decrease in DAS28 score of \>1.2 from baseline.
Time frame: Days 169, 729, 1261, 1821
Open-Label LT Period: Number of Participants Achieving DAS 28 Remission at Days 169, 729, 1261, 1821
The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6.
Time frame: Days 169, 729, 1261, 1821
Open-Label LT Period: Number of Participants Achieving DAS 28 Low Disease Activity (LDA) at Days 169, 729, 1261, 1821
The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6.
Time frame: Days 169, 729, 1261, 1821
Open-Label LT Period: Number of Participants With HAQ-DI Response at Days 169, 729, 1261, 1821
The disability section of the full HAQ includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI overall score ranges from a minimum of 0 to a maximum of 3.0. HAQ response was defined as an improvement (reduction) from baseline (Day 1) of at least 0.3 units in the HAQ score.
Time frame: Days 169, 729, 1261, 1821
Open-Label LT Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation
AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug
Time frame: End of ST Period (Day 169) to last dose plus 85 days, up to 5 years (September 2014)
Open-Label LT Period: Number of Participants With AEs of Special Interest
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections, serious infections, and opportunistic infections; autoimmune disorders; malignancies; system injection reactions, and local injection site reactions.
Time frame: End of ST Period (Day 169) to last dose plus 85 days, up to 5 years (September 2014)
Open-Label LT Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements
Vital sign assessments were performed in the LT period at 12-week intervals and at a yearly visit (at 16-week intervals) and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Vital signs included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.
Time frame: End of ST Period (Day 169) to last dose plus 7 days, up to 5 years (September 2014)
Open-Label LT Period: Number of Participants With Clinically Significant Laboratory Abnormalities
Laboratory assessments were performed in the LT period at 12-week intervals and at a yearly visit and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Abnormalities were determined to be clinically significant by the investigator.
Time frame: End of ST Period (Day 169) to last dose plus 7 days, up to 5 years (September 2014)
During the double blind short term (ST) period of the Main study, a sub-study in RA participants was initiated to evaluate anti-tumor necrosis factor (TNF) failure population. The sub-study was terminated early due to slow recruitment and participants from the sub-study were allowed to roll into the Main study during the LT Open Label Period.
| Milestone | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept |
|---|---|---|
| Started | 736 | 721 |
| Completed | 693 | 676 |
| Not completed | 43 | 45 |
| Withdrew: Adverse event | 17 | 25 |
| Withdrew: Withdrawal by subject | 11 | 5 |
| Withdrew: Lost to follow-up | 0 | 6 |
| Withdrew: Administrative reason by sponsor | 1 | 0 |
| Withdrew: Death | 1 | 1 |
| Withdrew: No longer meets study criteria | 2 | 1 |
| Withdrew: Lack of efficacy | 6 | 1 |
| Withdrew: Poor/non-compliance | 3 | 0 |
| Withdrew: Missed doses | 0 | 1 |
| Withdrew: Incomplete breast exam | 0 | 1 |
| Withdrew: Suspended drug due to surgery | 0 | 1 |
| Withdrew: Early discontinuation | 0 | 1 |
| Withdrew: Participant weight gain | 1 | 0 |
| Withdrew: Participant withdrew-recurrent infection | 0 | 1 |
| Withdrew: Investigator decision | 0 | 1 |
| Withdrew: Ongoing infection risk | 1 | 0 |
| Milestone | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept |
|---|---|---|
| Started | 8 | 10 |
| Completed | 7 | 9 |
| Not completed | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Milestone | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept |
|---|---|---|
| Started | 1373 | 0 |
| Completed | 945 | 0 |
| Not completed | 428 | 0 |
| Withdrew: Adverse event | 100 | 0 |
| Withdrew: Withdrawal by subject | 81 | 0 |
| Withdrew: Pregnancy | 16 | 0 |
| Withdrew: Lost to follow-up | 32 | 0 |
| Withdrew: Administrative reason by sponsor | 9 | 0 |
| Withdrew: Death | 20 | 0 |
| Withdrew: No longer met criteria | 1 | 0 |
| Withdrew: Lack of efficacy | 89 | 0 |
| Withdrew: Poor/non-compliance | 8 | 0 |
| Withdrew: Non-specified | 71 | 0 |
| Withdrew: No end of study status page | 1 | 0 |
The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169 | 527 | 514 |
The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| ACR 50 | 357 | 341 |
| ACR 70 | 183 | 170 |
The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered.
| units on a scale | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Double-blind Period: Mean Baseline Health Assessment Questionnaire Disability Index (HAQ-DI) for Participants With Assessments at Day 169 | 1.72 ± 0.68 | 1.67 ± 0.67 |
The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0.
| units on a scale | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Double-blind Period: Adjusted Mean Change From Baseline to Day 169 in HAQ-DI | -0.69 ± 0.02 | -0.70 ± 0.02 |
The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ-DI response=an improvement of at least 0.3 units from baseline in HAQ-DI.
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Double-blind Period: Number of Participants Achieving Clinically Meaningful HAQ-DI Response at Day 169 | 483 | 442 |
AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Deaths | 2 | 5 |
| SAEs | 31 | 35 |
| Treatment-related SAEs | 5 | 12 |
| SAEs Leading to Discontinuation | 8 | 14 |
| AEs | 493 | 470 |
| Treatment-related AEs | 204 | 210 |
| AEs Leading to Discontinuation | 15 | 25 |
AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
| participants | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept |
|---|---|---|
| Deaths | 0 | 0 |
| SAEs | 0 | 0 |
| AEs Leading to Discontinuation | 0 | 0 |
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections,serious infections,and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (prespecified AEs occurring within 1 hr of start of infusion), peri-infusional AEs (prespecified AEs occurring within 24 hrs of the start of infusion), system injection reactions, and local injection site reactions
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Infections | 234 | 221 |
| Malignancies | 3 | 5 |
| Autoimmune Disorders | 7 | 6 |
| Acute Infusional AEs | 20 | 16 |
| Peri-infusional AEs | 59 | 59 |
| Local Injection Site Reactions | 19 | 18 |
| Systemic Injection Reactions | 56 | 56 |
Vital sign measurements were performed for participants before and after infusion/subcutaneous injection of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Double-blind Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements | 0 | 0 |
ULN=upper limit of normal; LLN=lower limit of normal; BL= baseline. Marked abnormality criteria: Hemoglobin: \>3 g/dL decrease from BL; hematocrit: \<0.75\*BL; erythrocytes: \<0.75\*BL; platelets: \<0.67\*LLN/\>1.5\*ULN, or if BL\<LLN, use \<0.5\*BL and \<100,000 mm\^3; leukocytes: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN use \<0.8\*BL or \>ULN, or if BL\>ULN, use \>1.2\*BL or \<LLN; neutrophils+bands: \<1.0\*10\^3 c/uL; eosinophils: \>0.750\*10\^3 c/uL; basophils: \>400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750\*10\^3 c/uL/\>7.50\*10\^3 c/uL.
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Low hemoglobin (LLN=11.5 g/dL); n=729, 713 | 2 | 5 |
| Low hematocrit (LLN=34%); n=726, 713 | 2 | 4 |
| Low erythrocytes(LLN=3.8 x10*6c/uL);n=729, 713 | 2 | 3 |
| Low platelets (LLN=140*10^9 c/L); n=725, 709 | 1 | 0 |
| High platelets (ULN=450*10^9 c/L); n=725, 709 | 0 | 0 |
| Low leukocytes (LLN= 3.8*10^3 c/uL); n=729, 713 | 6 | 2 |
| High leukocytes (ULN = 10.6*10^3 c/uL);n=729, 713 | 25 | 18 |
| Low neutrophils+bands(LLN=1.8*10^3 c/uL);n=730,713 | 0 | 0 |
| High eosinophils (ULN= 7*10^3 c/uL); n=730, 712 | 22 | 16 |
| High basophils (ULN= 0.2*10^3 c/uL); n=730, 712 | 0 | 0 |
| High monocytes (ULN=1*10^3 c/uL); n=730, 712 | 0 | 1 |
| Low lymphocytes (LLN= 0.7*10^3 c/uL);n=730,712 | 40 | 42 |
| High lymphocytes(ULN=4.5*10^3 c/uL);n=730,712 | 40 | 42 |
Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\*ULN, or if BL\>ULN, use \>3\*BL; aspartate aminotransferase (AST): \>3\*ULN, or if BL\>ULN, use \>4\*BL; alanine aminotransferase (ALT): \>3\*ULN, or if BL\>ULN, use \>4\*BL; G-glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN, use \>3\*BL; bilirubin: \>2\* ULN, or if BL\>ULN, use \>4\*BL; blood urea nitrogen: \>2\* BL; creatinine: \>1.5\*BL
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| High ALP (ULN=400 U/L); n=730, 713 | 1 | 3 |
| High AST (ULN=44 U/L); n=729, 713 | 5 | 5 |
| High ALT (ULN=55 U/L);n=729, 713 | 12 | 16 |
| High GGT (ULN=65 U/L); n=730, 713 | 8 | 14 |
| High bilirubin (ULN=1.2 mg/dL); n=730, 713 | 1 | 0 |
| High blood urea nitrogen (26 mg/dL); n=730, 713 | 21 | 27 |
| High creatinine (ULN=1.5 mg/dL); n=730, 713 | 19 | 30 |
Marked abnormality criteria: Sodium: \<0.95\*LLN/\>1.05\*ULN, or if BL\<LLN, use \<0.95\* BL or \>ULN, or if BL\>ULN, use\>1.05\* BL or \<LLN; potassium: \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN, use\>1.1\* BL or \<LLN; chlorine: \<0.9\*LLN/\>1.1\* ULN, or if BL\<LLN, use \<0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN; calcium: \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN, use \<0.75\*BL or \>ULN, or if BL\>ULN, use\>1.25\* BL or \<LLN; phosphorous: \<0.75\* LLN/\>1.25\*ULN, or if BL\<LLN, use 0.67\*BL or \>ULN, or if BL\>ULN, use\>1.33\* BL or \<LLN
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Low sodium (LLN=135 mEq/L) | 2 | 0 |
| High sodium (ULN=148 mEq/L) | 0 | 0 |
| Low potassium (LLN=3.5 mEq/L) | 9 | 9 |
| High potassium (ULN=5.5 mEq/L) | 1 | 0 |
| Low chlorine (LLN= 96 mEq/L) | 0 | 0 |
| High chlorine (ULN=109 mEq/L) | 0 | 0 |
| Low calcium (LLN=8.4 mg/dL) | 1 | 0 |
| High calcium (ULN=10.6 mg/dL) | 1 | 0 |
| Low phosphorous (LLN=0.8 mg/dL) | 1 | 2 |
| High phosphorous (ULN=5.6 mg/dL) | 0 | 1 |
| µg/mL | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Day 57 (n=25, n=16) | 31.60 ± 21.483 | 23.14 ± 14.008 |
| Day 85 (n=630, n=649) | 28.30 ± 21.692 | 20.00 ± 13.441 |
| Day 113 (n=44, n=29) | 26.49 ± 16.569 | 18.76 ± 16.322 |
| Day 120 (n=27) | 25.10 ± 14.933 | NA ± NA |
| Day 127 (n=28) | 29.16 ± 14.780 | NA ± NA |
| Day 134 (n=27) | 25.10 ± 15.753 | NA ± NA |
| Day 141 (n=26, n=26) | 25.79 ± 14.264 | 18.10 ± 17.717 |
| Day 169 (n=530, n=521) | 24.91 ± 14.989 | 18.10 ± 17.94 |
Serum concentrations of abatacept were analyzed using a validated ELISA. Steady-state trough observed concentration in serum (Cminss) was measured in μg/mL. Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169.
| μg/mL | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept |
|---|---|---|
| Day 57 (n=3,4) | 25.53 ± 16 | 15.51 ± 25 |
| Day 85 (n=6,9) | 21.51 ± 26 | 12.50 ± 48 |
| Day 113 (n=6,6) | 23.14 ± 27 | 11.10 ± 31 |
| Day 120 (n=4) | 25.75 ± 17 | NA ± NA |
| Day 127 (n=3) | 25.42 ± 9 | NA ± NA |
| Day 134 (n=3) | 25.55 ± 13 | NA ± NA |
| Day 141 (n=4,6) | 20.85 ± 24 | 8.34 ± 44 |
| Day 169 (n=5,7) | 19.66 ± 25 | 9.00 ± 53 |
| µg/mL | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Double-blind Period: Maximum Observed Serum Concentration of Abatacept | 40.39 ± 30.148 | 222.35 ± 71.920 |
Serum concentrations of abatacept were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169. Cmax was measured in micrograms per milliliter (μg/mL).
| μg/mL | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept |
|---|---|---|
| Anti-TNF Failure Substudy Double Blind Period: Geometric Mean Maximum Observed Serum Concentration of Abatacept | 35.84 ± 24 | 229.88 ± 26 |
| µg*h/mL | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Double-blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept | 5182.37 ± 2854.136 | 39587.08 ± 15444.743 |
Serum concentrations of abatacept were analyzed using a validated ELISA. AUC(TAU) was measured as μg\*h/mL. Samples for AUC (TAU) were obtained on Days 113, 120, 127, 134, and 141.
| μg*h/mL | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept |
|---|---|---|
| Anti-TNF Failure Sub-study Double Blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept | 4384.80 ± 17 | 34260.55 ± 35 |
Serum samples from all treated adult participants with active rheumatoid arthritis were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept (anti-ABA) or anti-CTLA4 antibody (anti-CTLA4).
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Day 85 anti-ABA (n=700, n=682) | 0 | 2 |
| Day 85 anti-CTLA4 (n=705, n=689 | 0 | 0 |
| Day 85 total (n=706, n=689) | 0 | 2 |
| Day 169 anti-ABA (n=671, n=648) | 3 | 4 |
| Day 169 anti-CTLA4 (n=681, n=658) | 2 | 4 |
| Day 169 total (n=681, n=658) | 5 | 8 |
| Overall on-treatment visits anti-ABA (n=707, 691) | 3 | 5 |
| Overall on-treatment visits anti-CTLA4 (n=716,702) | 2 | 4 |
| Overall on-treatment visits total (n=716, 702) | 5 | 9 |
| 28 days post last dose anti-ABA (n=18, n=25) | 0 | 0 |
| 28 days post last dose anti-CTLA4 (n=20, n=27) | 0 | 2 |
| 28 days post last dose total (n=20, n=27) | 0 | 2 |
| 56 days post last dose anti-ABA (n=19, n=22) | 0 | 0 |
| 56 days post last dose anti-CTLA4 (n=19, n=23) | 1 | 1 |
| 56 days post last dose total (n=19, n=23) | 1 | 1 |
| 85 days post last dose anti-ABA (n=12, n=15) | 0 | 0 |
| 85 days post last dose anti-CTLA4 (n=13, n=15) | 2 | 5 |
| 85 days post last dose total (n=13, n=15) | 2 | 5 |
| Overall post visits anti-ABA (n=26, n=29) | 0 | 0 |
| Overall post visits anti-CTLA4 (n=28, n=31) | 3 | 7 |
| Overall post visits total (n=28, n=31) | 3 | 7 |
| Overall anti-ABA (n=714, n=698) | 3 | 5 |
| Overall anti-CTLA4 (n=725, n=710) | 5 | 11 |
| Overall total (n=725, n=710) | 8 | 16 |
C-reactive protein is an acute phase reactant protein that is a clinical marker for rheumatoid arthritis. Time-matched median percent change from baseline= (time-matched baseline value - Post-baseline value)/time-matched baseline value\*100, where the time-matched baseline value represents the median baseline value for only that cohort of participants with measurements available at that visit.
| percent change | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Day 15 (n=720, n=703) | 34.16 (-11.11 to 58.80) | 33.74 (-6.24 to 58.41) |
| Day 29 (n=727, n=711) | 39.74 (3.83 to 66.99) | 42.52 (0.42 to 68.66) |
| Day 57 (n=727, n=711) | 47.88 (6.84 to 73.53) | 51.42 (7.53 to 74.95) |
| Day 85 (n=727, n=711) | 52.90 (8.70 to 78.25) | 53.65 (11.05 to 79.42) |
| Day 113 (n=727, n=711) | 53.33 (7.09 to 80.29) | 58.12 (11.21 to 81.26) |
| Day 141 (n=727, n=711) | 56.12 (5.28 to 83.24) | 58.39 (16.14 to 81.52) |
| Day 169 (n=727, n=711) | 57.18 (11.18 to 83.28) | 56.81 (17.92 to 82.70) |
An electrochemiluminescence immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; abatacept molecule). Ig and/or Junction (JNCT) category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a postbaseline titer higher than Baseline, or any postbaseline positivity if Baseline value was missing. Trt=treatment.
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Day 85 CTLA4 + possibly Ig (n=78, n=67) | 0 | 0 |
| Day 85 Ig +/- JNCT (n=78, n=67) | 0 | 0 |
| Day 85 total (n=78, n=67) | 0 | 0 |
| Day 169 CTLA4 + possibly Ig (n=75, n=67) | 0 | 1 |
| Day 169 Ig +/- JNCT (n=75, n=67) | 0 | 0 |
| Day 169 total (n=75, n=67) | 0 | 1 |
| Overall on-TRT CTLA4 + possibly Ig (n=79, 70) | 0 | 1 |
| Overall on-TRT Ig +/- JNCT (n=79, 70) | 0 | 0 |
| Overall on-TRT total (n=79, 70) | 0 | 1 |
| 28 days post last dose CTLA4+possibly Ig (n=2,n=2) | 0 | 0 |
| 28 days post last dose Ig +/- JNCT (n=2, n=2) | 0 | 0 |
| 28 days post last dose Total (n=2, n=2) | 0 | 0 |
| 56 days post last dose CTLA4+possibly Ig (n=2,n=2) | 0 | 0 |
| 56 days post last dose Ig +/- JNCT (n=2, n=2) | 0 | 0 |
| 56 days post last dose total (n=2, n=2) | 0 | 0 |
| 85 days post last dose CTLA4+possibly Ig (n=1,n=1) | 0 | 0 |
| 85 days post last dose Ig +/- JNCT (n=1, n=1) | 0 | 0 |
| 85 days post last dose total (n=1, n=1) | 0 | 0 |
| Overall post visits CTLA4+possibly Ig (n=3, n=2) | 0 | 0 |
| Overall post visits Ig +/- JNCT (n=3, n=2) | 0 | 0 |
| Overall post visits total (n=3, n=2) | 0 | 0 |
| Overall CTLA4+possibly Ig (n=82, n=71) | 0 | 1 |
| Overall Ig +/- JNCT (n=82, n=71) | 0 | 0 |
| Overall total (n=82, n=71) | 0 | 1 |
Rheumatoid factor (RF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Baseline RF negative | 106 | 93 |
| Baseline RF negative; Day 169 RF positive | 2 | 3 |
| Baseline RF positive | 586 | 582 |
| Baseline RF positive ; Day 169 RF negative | 33 | 40 |
The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).
| participants | Open-Label SC Abatacept Long Term Period |
|---|---|
| Day 169 (n=1357) | 1087 |
| Day 729 (n=1187) | 973 |
| Day 1261 (n=1068) | 904 |
| Day 1821 (n=421) | 356 |
The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.
| participants | Open-Label SC Abatacept Long Term Period |
|---|---|
| Day 169 ACR 50 (n=1362) | 724 |
| Day 729 ACR 50 (n=1185) | 720 |
| Day 1261 ACR 50(n=1069) | 672 |
| Day 1821 ACR 50 (n=423) | 277 |
| Day 169 ACR 70 (n=1362) | 371 |
| Day 729 ACR 70 (n=1186) | 443 |
| Day 1261 ACR 70 (n=1070) | 438 |
| Day 1821 ACR 70 (n=425) | 191 |
The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6. A clinically significant response= decrease in DAS28 score of \>1.2 from baseline.
| units on a scale | Open-Label SC Abatacept Long Term Period |
|---|---|
| Day 169 (n=1353) | -2.65 (-2.71 to -2.58) |
| Day 729 (n=1181) | -2.94 (-3.01 to -2.86) |
| Day 1261 (n=1063) | -3.09 (-3.17 to -3.00) |
| Day 1821 (n=413) | -3.24 (-3.38 to -3.11) |
The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6.
| participants | Open-Label SC Abatacept Long Term Period |
|---|---|
| Day 169 (n=1355) | 334 |
| Day 729 (n=1183) | 411 |
| Day 1261 (n=1064) | 425 |
| Day 1821 (n=413) | 169 |
The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6.
| participants | Open-Label SC Abatacept Long Term Period |
|---|---|
| Day 169 (n=1355) | 553 |
| Day 729 (n=1183) | 600 |
| Day 1261 (n=1064) | 585 |
| Day 1821 (n=413) | 238 |
The disability section of the full HAQ includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI overall score ranges from a minimum of 0 to a maximum of 3.0. HAQ response was defined as an improvement (reduction) from baseline (Day 1) of at least 0.3 units in the HAQ score.
| participants | Open-Label SC Abatacept Long Term Period |
|---|---|
| Day 169 (n=1364) | 962 |
| Day 729 (n=1190) | 853 |
| Day 1261 (n=1068) | 780 |
| Day 1821 (n=427) | 315 |
Serum samples from all treated adult participants with active rheumatoid arthritis who were from the Anti-TNF failure population were screened for the presence of drug-specific antibodies using Enzyme Linked Immunoabsorbant Assay (ELISA). The number of participants who had the presence of anti-abatacept antibodies or anti-CTLA-4 antibodies present in their serum are summarized.
| participants | Subcutaneous Abatacept | Intravenous Abatacept |
|---|---|---|
| Day 85 Anti-abatacept (n=8,10) | 0 | 0 |
| Day 85 Anti-CTLA4-T (n=8,10) | 0 | 0 |
| Day 169 Anti-abatacept (n=6,9) | 0 | 0 |
| Day 169 Anti-CTLA4-T(n=6,9) | 1 | 0 |
| Overall Treatment Anti-abatacept (n=8,10) | 0 | 0 |
| Overall on Treatment Anti-CTLA4-T(n=8,10) | 1 | 0 |
| 28 days post Anti-abatacept (n=1,1) | 0 | 0 |
| 28 days post Anti-CTLA4-T (n=1,1) | 0 | 0 |
| 56 days post Anti-abatacept (n=0,1) | 0 | 0 |
| 56 days post Anti-CTLA4-T (n=0,1) | 0 | 0 |
| 85 days post Anti-abatacept (n=0,1) | 0 | 0 |
| 85 days post Anti-CTLA4-T (n=0,1) | 0 | 0 |
AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug
| participants | Open-Label SC Abatacept Long Term Period |
|---|---|
| Death | 41 |
| SAE | 353 |
| Treatment-related SAE | 88 |
| SAEs leading to Discontinuation | 73 |
| Treatment-related AEs | 632 |
| AEs leading to Discontinuation | 97 |
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections, serious infections, and opportunistic infections; autoimmune disorders; malignancies; system injection reactions, and local injection site reactions.
| participants | Open-Label SC Abatacept Long Term Period |
|---|---|
| All Infections | 962 |
| Serious Infections | 85 |
| Infections leading to Discontinuation | 25 |
| Serious Infections leading to Discontinuation | 16 |
| Malignancies | 56 |
| Autoimmune Disorders | 67 |
| Local Injection Site Reactions | 33 |
| Systemic Injection Reactions | 161 |
Vital sign assessments were performed in the LT period at 12-week intervals and at a yearly visit (at 16-week intervals) and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Vital signs included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.
| participants | Open-Label SC Abatacept Long Term Period |
|---|---|
| Open-Label LT Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements | 0 |
Laboratory assessments were performed in the LT period at 12-week intervals and at a yearly visit and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Abnormalities were determined to be clinically significant by the investigator.
| participants | Open-Label SC Abatacept Long Term Period |
|---|---|
| Open-Label LT Period: Number of Participants With Clinically Significant Laboratory Abnormalities | 0 |
Collected over First dose (Day 1) in ST period to last dose in LT period plus 85 days, up to 5 years (September 2014).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV Abatacept | — | 206/731 (28.2%) | 544/731 (74.4%) |
| SC Abatacept | — | 199/744 (26.7%) | 567/744 (76.2%) |
| Event | IV Abatacept | SC Abatacept |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 12/731 | 16/744 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 12/731 | 14/744 |
| PneumoniaInfections and infestations | 12/731 | 8/744 |
| Myocardial infarctionCardiac disorders | 5/731 | 11/744 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/731 | 2/744 |
| Urinary tract infectionInfections and infestations | 7/731 | 1/744 |
| Chest painGeneral disorders | 6/731 | 4/744 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/731 | 6/744 |
| Acute myocardial infarctionCardiac disorders | 1/731 | 5/744 |
| CholelithiasisHepatobiliary disorders | 4/731 | 2/744 |
| Event | IV Abatacept | SC Abatacept |
|---|---|---|
| Urinary tract infectionInfections and infestations | 133/731 | 150/744 |
| NasopharyngitisInfections and infestations | 143/731 | 149/744 |
| Upper respiratory tract infectionInfections and infestations | 131/731 | 130/744 |
| BronchitisInfections and infestations | 120/731 | 109/744 |
| HypertensionVascular disorders | 85/731 | 96/744 |
| DiarrhoeaGastrointestinal disorders | 89/731 | 96/744 |
| HeadacheNervous system disorders | 88/731 | 86/744 |
| PharyngitisInfections and infestations | 80/731 | 74/744 |
| NauseaGastrointestinal disorders | 53/731 | 79/744 |
| Back painMusculoskeletal and connective tissue disorders | 76/731 | 76/744 |
Per-protocol Population in ST Period.
| Age, Continuous(years) | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept | Total |
|---|---|---|---|
| Mean | 49.9 ± 13.0 | 49.9 ± 12.7 | 49.9 ± 12.8 |
| Sex: Female, Male(Participants) | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept | Total |
|---|---|---|---|
| Female | 586 | 549 | 1135 |
| Male | 110 | 134 | 244 |
| Race (NIH/OMB)(Participants) | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept | Total |
|---|---|---|---|
| American Indian or Alaska Native | 5 | 1 | 6 |
| Asian | 63 | 72 | 135 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 26 | 24 | 50 |
| White | 516 | 505 | 1021 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 86 | 81 | 167 |
| Region Of Enrollment(participants) | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept | Total |
|---|---|---|---|
| North America | 129 | 111 | 240 |
| South America | 338 | 340 | 678 |
| Europe | 123 | 123 | 246 |
| Rest of the World | 106 | 109 | 215 |
| Baseline Weight Category(participants) | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept | Total |
|---|---|---|---|
| <60 kg | 175 | 171 | 346 |
| 60 to 100 kg | 464 | 465 | 929 |
| >100 kg | 57 | 47 | 104 |
| Duration of RA Disease(years) | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept | Total |
|---|---|---|---|
| Mean | 7.6 ± 8.0 | 7.7 ± 7.9 | 7.7 ± 7.9 |
| Duration of Disease Category(participants) | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept | Total |
|---|---|---|---|
| ≤2 Years | 229 | 206 | 435 |
| 2 - ≤5 yrs | 144 | 145 | 289 |
| 5 - ≤10 yrs | 134 | 155 | 289 |
| > 10 yrs | 189 | 177 | 366 |
| Number of Tender Joints(tender joints) | Subcutaneous (SC) Abatacept | Intravenous (IV) Abatacept | Total |
|---|---|---|---|
| Mean | 30 ± 14.1 | 29.2 ± 13.1 | 29.6 ± 13.6 |
10 further baseline measures are reported on the registry.
Showing the first 100 of 204 sites across 24 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2008, a primary completion of Nov 2009 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept